摘要
目的:观察利福平注射液-胶囊序贯治疗复治涂阳肺结核强化期的疗效。方法:80例复治涂阳肺结核患者随机分为治疗组(40例)与对照组(40例),强化期分别采用HZES+利福平注射液-胶囊序贯治疗和HZES+单纯口服利福平胶囊方案治疗;追踪观察强化期1、2个月末痰菌阴转、肺部病灶吸收及毒副反应情况。结果:1、2个月末痰菌阴转率,治疗组分别为82.5%、97.5%,对照组分别为65.0%、85.0%;1、2个月末胸部X线影像学检查显效率,治疗组分别为17.5%、40.0%,对照组分别为10.0%、25.0%;治疗组与对照组2个月末空洞闭合、缩小率分别为41.7%、22.7%,肝功能异常发生率分别为22.5%、25.0%,胃肠道反应发生率分别为20.0%、45.0%。结论:利福平注射液-胶囊序贯治疗起效快、效果佳、副反应少,在控制症状、缩短排菌时间、减少副反应及抢救重症结核病上有很好的效果。
OBJECTIVE： To observe the curative effect of Rifampicin Injection - Capsule sequential therapy for retreatment of smear positive pulmonary tuberculosis （TB） at intensive stage. METHODS： 80 patients with smear positive pulmonary tuberculosis at intensive stage were enrolled： 40 （treatment group） were randomly assigned to receive HZES plus Rifampicin Injection-Capsule sequential therapy, and another 40 （control group） to receive HZES plus Rifampicin capsule. Follow - up of sputum negative conversion rate, pulmonary lesion, and toxcity were scheduled at the end of first and second month during intensified stage. RESULTS： At the end of first and second month during intensified stage, the sputum negative conversion rates were 82.5% and 97.5% respectively in the treatment group versus 65.0% and 85.0% respectively in control gorup; the X- ray imaging test of chests revealed that the responsive rates were 17.5% and 40.0% in the treatment groups versus 10.0% and 25.0% in the control group. At the end of second month, the cavity closure （or diminution） rate was 41.7% in the treatment group versus 22.7% in the control group; the incidence of hepatic lesion was 22.5% verus 25.0% and that of gastrointestinal tract toxcity was 20.0% versus 45.0%. CONCLUSION： Rifampicin Injection- Capsule sequential therapy was proved to be of rapid onset of effect, remarkable efficacy, less toxicity and satisfactory efficacy in controlling symptom, shortening bacterial clearance time, reducing side effects and treating severe TB.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第26期2052-2053,共2页
China Pharmacy
关键词
肺结核
化疗
利福平
Pulmonary tuberculosis （TB）
Chemotherapy
Rifampicin
